Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug

The Centers for Medicare and Medicaid Services will formally consider whether to adopt nationwide rules for coverage of Biogen's new Alzheimer's drug Aduhelm, announcing Monday the opening of a determination process that could shape how millions of Americans are able to access the controversial treatment.